HER2 low breast cancer

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…

This phase 2 trial is testing two antibody-drug conjugates—trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan (Dato-DXd)—in people with HER2-negative metastatic breast cancer whose disease has worsened after prior antibody-drug conjugate therapy. Participants will receiv…

This phase 2 trial tests a combination of two drugs—disitamab vedotin and bevacizumab—in 37 people with HER2-low metastatic breast cancer whose disease progressed after prior T-DXd therapy. The goal is to see if the combo can shrink tumors and delay progression. Researchers will …

This study is tracking 300 people with HER2-positive or HER2-low breast cancer who are receiving trastuzumab-rezetecan as part of their routine care. Researchers are monitoring side effects and how well the drug works in real-world conditions, not in a strict lab setting. The goa…

This study tests a new drug called BL-M07D1 against standard chemotherapy in 566 adults with HER2-low breast cancer that has come back or spread. The goal is to see if BL-M07D1 can slow the cancer's growth better than current treatments. Participants must be women aged 18 to 75 w…

This study is tracking 800 Chinese patients with advanced HER2-positive or HER2-low breast cancer who are receiving trastuzumab deruxtecan (T-DXd) in real-world clinics. Researchers want to see how long patients stay on treatment and how well it works outside of clinical trials. …

This study tests a special PET scan that uses a radioactive tracer to detect HER2 protein on cancer cells. The goal is to see if this scan can better identify which patients with metastatic breast cancer will benefit from a targeted drug called T-DXd. About 70 women with advanced…

This observational study looks at 255 women with HER2-low breast cancer to understand how certain gene changes (HRD/HRR) relate to survival. Researchers will analyze tumor and blood samples to map these genetic features. The goal is to learn more about this cancer type, not to te…